Capsomere, Recombinant Human Adeno-Associated Virus Aav3B Viral Capsid Protein Vp1-Vp2-Vp3 Complex (1:2:7), Hexacontamer, Complex With Dna (Recombinant Replication-Defective Adeno-Associated Virus Serotype 3B Vector Vtx-801 Liver-Specific Human ?-1 Antitrypsin Promoter Plus Human 57-486-Copper Transporter Atp7B Codon-Optimized Gene Plus Rabbit ?-Globin Polyadenylation Signal Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) (1:1)
Wilson Disease
Explore 11 assets in Wilson Disease →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Vivet Therapeutics SAS
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04537377CT.gov A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Wilson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capsomere, Recombinant Human Adeno-Associated Virus Aav3B Viral Capsid Protein Vp1-Vp2-Vp3 Complex (1:2:7), Hexacontamer, Complex With Dna (Recombinant Replication-Defective Adeno-Associated Virus Serotype 3B Vector Vtx-801 Liver-Specific Human ?-1 Antitrypsin Promoter Plus Human 57-486-Copper Transporter Atp7B Codon-Optimized Gene Plus Rabbit ?-Globin Polyadenylation Signal Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) (1:1) (this asset) | Vivet Therapeutics SAS | P1/2 | CCC · 48 |
| Zinc Acetate | Nobelpharma | P4 | BBB |
| Teta 4Hcl | Orphalan | P3 | BBB |
| Zinc D-Gluconate (1:2) | Jun Li | P4 | BBB |
| Trientine | Excelsior | P3 | BB |
| Penicillamine | Orphalan | P3 | BB |
| Alxn1840 | Alexion Pharmaceuticals, Inc. | P3 | BB |
| Gandouling | Jun Li | P4 | BB |
| Tetrathiomolybdate | National Center for Research Resources (NCRR) | P3 | B |
+11 more in the Wilson Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capsomere, Recombinant Human Adeno-Associated Virus Aav3B Viral Capsid Protein Vp1-Vp2-Vp3 Complex (1:2:7), Hexacontamer, Complex With Dna (Recombinant Replication-Defective Adeno-Associated Virus Serotype 3B Vector Vtx-801 Liver-Specific Human ?-1 Antitrypsin Promoter Plus Human 57-486-Copper Transporter Atp7B Codon-Optimized Gene Plus Rabbit ?-Globin Polyadenylation Signal Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) (1:1) in Wilson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capsomere-recombinant-human-adeno-associated-virus-aav3b-viral-capsid-protein-vp1-vp2-vp3-complex-127-hexacontamer-complex-with-dna-recombinant-replication-defective-adeno-associated-virus-serotype-3b-vector-vtx-801-liver-specific-human-1-antitrypsin-promoter-plus-human-57-486-copper-transporter-atp7b-codon-optimized-gene-plus-rabbit-globin-polyadenylation-signal-plus-adeno-associated-virus-2-inverted-terminal-repeat-flanks-11-wilson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →